Picture Kentro Design Corporate and Web Design Berlin 650x65px
Document › Details

Numab Therapeutics AG. (12/12/19). "Press Release: Numab Therapeutics and 3SBio’s Subsidiary Sunshine Guojian Form Partnership to Develop a Portfolio of Novel Multi-specific Antibodies in Immuno-Oncology". Wädenswil, Shengyang & Shanghai.

Region Region China
Organisations Organisation Numab Therapeutics AG
  Group Numab (Group)
  Organisation 2 Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (SSE: 688336)
  Group 3SBio (Group)
Products Product MATCH™ platform (Numab)
  Product 2 antibody cancer drug
Index terms Index term 3SBio–Numab: antibody cancer drug, 201912– collab developm + commercialisation with Sunshine Guojian for multi-specific Abs in Greater China
  Index term 2 Numab–3SBio: investment, 201912–202003 financing round Series B totalling CHF22m incl CHF15m from new investor 3SBio/Sunshine Guojian
Person Person Urech, David (Numab 201910 CEO + Co-Founder before Esbatech 2004–2010)

New partner invests CHF15M as part of Numab’s Series B financing

Numab Therapeutics ( “Numab”) and 3SBio Inc. (“3SBio”,HKEX:1530) announced today that 3SBio’s subsidiary Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (“Sunshine Guojian”) and Numab have formed a partnership focusing on the development and commercialization of a portfolio of novel multi-specific antibodies for the therapy of cancer based on Numab’s technology platform. Under the agreement, Sunshine Guojian has the right to select up to five antibody molecules emerging from up to three multispecific antibody programs based on Numab’s R&D platform and has the exclusive licenses to develop and commercialize each of the selected antibody molecules in Greater China territories, including the Mainland China, Hong Kong, Macao and Taiwan, while Numab retains exclusive commercial rights in the rest of the world. Concurrently, Sunshine Guojian has invested CHF15M (approximately USD 15.2M) in Numab’s series B financing. Dr. Zhenping Zhu, MD, PhD, President of Research and Development, Chief Scientific Officer of 3SBio, has joined Numab’s board of directors. Further financial terms were not disclosed.

“Numab’s proprietary MATCH™ technology has generated a robust pipeline of multi-specific antibody drug candidates with our lead program ND021, an anti-4-1BB x PD-L1 x HSA tri-specific antibody, entering clinical trials in 2020. The alliance with Sunshine Guojian is a continuation of our strategy to work with committed, world-class partners in Asia that are ideally positioned to develop and commercialize our multi-specific antibodies in this important region. Our partnering model has allowed us to establish a growing pipeline of innovative drug candidates and retain key commercial rights in Europe and the US,” commented Dr. David Urech, Chief Executive Officer of Numab Therapeutics. “Sunshine Guojian’s investment in our Series B will support Numab in the further expansion and advancement of our portfolio of multi-specific antibodies.”

“The investment and collaboration with Numab are consistent with our goal to explore promising therapeutic strategies that address the significant unmet medical needs of cancer patients in China,” said Dr. Jing Lou, Chairman and Chief Executive Officer of 3SBio. “Accessing Numab’s cutting-edge multispecific antibody technology platform and its product portfolio in immune-oncology complements our existing R&D establishment and strategy. 3SBio regards innovation in research and development as a main pillar of the enterprise and we are looking forward to collaborating with the Numab team.”

Multi-specific antibodies have the potential to unlock entirely novel modes-of-action aiming at superior benefit-to-risk profiles relative to conventional cancer immune therapies. Numab’s proprietary MATCH™ technology platform represents one of the most versatile and flexible sources for multi-specific antibodies. MATCH™ molecules can incorporate up to six binding specificities in true plug-and-play fashion. The individual antibody Fv building blocks are designed for maximum stability and developability.

About Numab Therapeutics

Numab Therapeutics is an oncology-focused biopharmaceutical company based in Zurich-area, Switzerland. At Numab, we are writing the next chapter in cancer immunotherapy by creating multispecific antibodies that enable the pursuit of novel therapeutic strategies. With our proprietary MATCH™ technology platform we are fueling a new wave of multi-specific drug candidates engineered with versatility and developability in mind. Our lead product was designed to balance potent anti-tumor immunity with a desirable safety profile by targeting 4-1BB, PD-L1 and Human Serum Albumin simultaneously. We believe meeting the highest quality standards in every step of the drug design process matters and will result in better patient outcomes. For further information, visit

About 3SBio

3SBio is a fully integrated biotechnology company in China with market-leading biopharmaceutical franchises in oncology, auto-immune diseases, nephrology, metabolic diseases and dermatology. 3SBio is focusing on building an innovative product pipeline, currently with over 30 product candidates under development. 3SBio’s manufacturing capabilities include recombinant proteins, monoclonal antibodies and chemically synthesized molecules, with research and production centers in Shenyang, Shanghai, Hangzhou, Shenzhen and Cuomo, Italy. Please visit for additional information.

About Sunshine Guojian

Sunshine Guojian was established in 2002 and is one of the first batch of innovative biopharmaceutical companies focusing on antibody drugs in China. It is the only domestic pharmaceutical company that has two launched therapeutic antibody drugs, and had emerged as a leader in antibody drug with its capabilities of independent R&D, industrialization and commercialization in China. Sunshine Guojian orients its R&D efforts primarily towards innovative therapeutic antibody drugs, and provides quality, safe and effective clinical solutions to the therapeutic areas of major diseases such as auto-immune diseases and tumors. Currently, Sunshine Guojian has 15 anti-body drug candidates (including 7 drug candidates in clinical and new drug registration stage and 8 drug candidates in pre-clinical stage) which are under different development stages, targeting tumor, auto-immune diseases and ophthalmological diseases. Most of those drug candidates are Category I biological products for therapeutic use or monoclonal antibodies, 2 of which are in application for launching, and 5 are in clinical stage. Sunshine Guojian may submit applications to both the China and the US Food and Drug Administration for some of those, or some of these drugs may be admitted for priority evaluation. Please visit for additional information.


For Numab Therapeutics
David Urech
Chief Executive Officer

For media
Sara Michelmore or Caroline Rufo, PhD.
+1 781-235-3060

For 3SBio and Sunshine Guojian
Zhang Hui
+86 21 50791207

Record changed: 2020-03-10


Picture ConsulTech GmbH RnD Credit Germany 650x80px

More documents for Numab (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80

» top